Colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer death in the United States, according to the American Cancer Society. It is also one of the most preventable — when it is caught early, the five-year survival rate exceeds 90%. The catch has always been that the gold-standard test, colonoscopy, asks a lot of patients: a day of bowel prep, sedation and time off work.
That is starting to change. Over the past few years, federal guidelines have expanded the menu of acceptable screening options, and a new generation of at-home stool tests and FDA-cleared blood tests have brought screening into the kitchen and the primary care office. Here is how the new landscape looks, and how the major options actually compare.
Why screening starts at age 45
In 2021 the U.S. Preventive Services Task Force lowered the recommended age to begin average-risk colorectal cancer screening from 50 to 45. The change followed a sharp rise in early-onset colorectal cancer, which has been climbing in adults under 50 since the mid-1990s. Researchers are still working out why, but suspected drivers include rising obesity, ultra-processed food intake, sedentary lifestyles, antibiotic exposure and changes in the gut microbiome.
The USPSTF now recommends screening every adult between 45 and 75. People at higher risk — a family history of colorectal cancer, a personal history of inflammatory bowel disease, or certain inherited syndromes — may need to start earlier and use specific tests. That decision belongs in a conversation with a qualified healthcare provider.
Colonoscopy: still the reference standard
During a colonoscopy, a gastroenterologist threads a flexible camera through the entire colon and rectum. It is the only test that can both detect and remove precancerous polyps in the same session, which is why it is sometimes called preventive rather than just diagnostic. A 2022 randomized trial published in The New England Journal of Medicine — the NordICC study of nearly 85,000 European adults — found that an invitation to colonoscopy reduced colorectal cancer risk by 18% over 10 years; among those who actually completed the test, the reduction was estimated at roughly 31%.
For people at average risk, current guidelines recommend a colonoscopy every 10 years. The trade-offs are real: bowel prep, sedation, a small risk of bleeding or perforation, and the time and cost of the procedure itself. Those barriers are part of the reason an estimated one in three U.S. adults aged 45 to 75 is not up to date on screening.
At-home stool tests
Fecal immunochemical test (FIT)
The FIT detects tiny amounts of human blood in a single stool sample. It is mailed back to a lab, costs little, and requires no diet or medication changes. Done every year, FIT performs well as a population screening tool. A 2017 meta-analysis in Annals of Internal Medicine reported sensitivity of about 79% for colorectal cancer and specificity above 94% when used annually.
FIT does not reliably detect precancerous polyps the way colonoscopy can. A positive FIT result is not a diagnosis — it is a signal that a follow-up colonoscopy is needed.
Multi-target stool DNA test (Cologuard)
Multi-target stool DNA tests combine the FIT antibody with a panel of DNA markers shed by abnormal cells. The most widely used version is performed every three years. In the pivotal 2014 trial published in The New England Journal of Medicine, the test detected 92% of colorectal cancers and 42% of advanced precancerous lesions — higher sensitivity than FIT alone, but with more false positives.
An updated next-generation version cleared by the FDA in 2024 improved both cancer detection and specificity, according to the BLUE-C trial in NEJM, which reported cancer sensitivity of about 94% and a meaningful reduction in false positives.
Blood-based screening
In 2024 the FDA approved Shield, the first blood test cleared as a primary screening option for average-risk adults. The test looks for fragments of tumor DNA and other markers circulating in the blood. In the ECLIPSE study, published in The New England Journal of Medicine, Shield detected 83% of colorectal cancers but only about 13% of advanced precancerous lesions — meaning it is much better at finding established cancer than at preventing it.
Blood-based tests are attractive because they can be drawn at a routine office visit, with no prep and no stool collection. The U.S. Preventive Services Task Force and major specialty groups have been clear that they should not be viewed as equivalent to colonoscopy or stool DNA testing for prevention. The role researchers see for them is closing the gap with people who would otherwise skip screening entirely. As with FIT and stool DNA, a positive result must be followed by a diagnostic colonoscopy.
How the options compare at a glance
- Colonoscopy — every 10 years; detects and removes polyps in one visit; gold-standard prevention; requires bowel prep and sedation.
- FIT (annual) — at-home stool; low cost; good cancer detection; misses most polyps; positives need colonoscopy.
- Stool DNA (every 3 years) — at-home; highest non-invasive cancer sensitivity; better polyp detection than FIT; more false positives.
- Blood test (Shield, every 3 years) — drawn in office; convenient; strong cancer detection; weak polyp detection; positives need colonoscopy.
Lifestyle still matters
Screening does not exist in a vacuum. Research summarized by the World Cancer Research Fund consistently links higher colorectal cancer risk to processed meat, heavy alcohol use, obesity and physical inactivity. Diets rich in whole grains, legumes, dairy and high-fiber plants are associated with lower risk. Regular physical activity — even brisk walking most days — appears to lower risk independently of weight.
The bottom line, according to gastroenterology societies, is that the best screening test is the one a person will actually complete. A perfect colonoscopy that never gets scheduled prevents nothing. A FIT card returned every year, or a stool DNA test every three years, or even a blood test that catches cancer early, all beat the alternative of no screening at all.
The takeaway
The expansion of screening options is good news for a disease that has been climbing in younger adults. Colonoscopy remains the most powerful tool for prevention, but at-home stool tests and the new blood test give people who have avoided screening a credible way to start. The right choice depends on personal risk, preferences and what is realistically going to get done — a conversation worth having with a primary care provider sooner rather than later.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.